Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 16/20 | 0.79 |
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12206759 | 1.00 | CCR2 (0.79) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL12207219 | 1.00 | CCR2 (0.79) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL196068 | 0.90 | CCR2 (0.91) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL12233199 | 0.90 | CCR2 (0.91) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL195030 | 0.90 | CCR2 (0.91) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL13605161 | 0.88 | CCR2 (1.00) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL12849253 | 0.88 | CCR2 (1.00) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL16104180 | 0.83 | CCR2 (0.81) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL6618485 | 0.82 | CCR2 (0.55) | CCR2CCR1CCR5CXCR4RAB9A | |
| SCHEMBL6618482 | 0.82 | CCR2 (0.55) | CCR2CCR1CCR5CXCR4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110150873-A1 | ANTI-INFLAMMATORY COMPOSITIONS AND COMBINATIONS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-06-23 | — | — | US | claimed |
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110150873-A1 | ANTI-INFLAMMATORY COMPOSITIONS AND COMBINATIONS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, CLN6 | CCR2 4494/4885CCR1 4474/4885CCR5 4410/4885 |
| US-20110150873-A1 | ANTI-INFLAMMATORY COMPOSITIONS AND COMBINATIONS | CCL2, CCL5, CXCL10 | CCR2 5/4885CCR1 11/4885CCR5 13/4885 |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | CLN6, NLN, ACHE | CCR2 4418/4885CCR1 4568/4885CCR5 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.